GRAND RAPIDS, Mich. (May 15, 2023) — Van Andel Institute has appointed Connie Chang as a board trustee at its meeting held May 15, 2023.
Chang brings deep knowledge and a diverse experience of academia, scientific research, life science industry and non-profit advisory leadership. She is currently the chief operating officer of ONL Therapeutics in Ann Arbor, leading strategy and operations for the biotech organization focused on vision and retinal disease. She has spent the last four years of her career in early-stage biotechs, building upon her earlier experience in large pharma and academic research. Chang also currently serves the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center as a member of the governing body for interdisciplinary partnership between University of Michigan, University of Pittsburgh, and the Wyss Institute at Harvard.
“While at the University of Michigan, I spent some time at Van Andel Institute exploring areas for collaboration, sharing insights and research,” Chang said. “I am very excited to effectively bridge conversations between operational leaders and scientists and help VAI make future strategic decisions.”
She joins board chair David Van Andel, and trustees John Kennedy and Mark Meijer. “We are thrilled to add Connie Chang and her perspective to our board of trustees,” Van Andel said. “She has proven to be a key driver of initiatives that have advanced medicine and science globally.”
Originally from Michigan and currently residing in Ann Arbor, Chang earned her bachelor’s in psychobiology and MBA in business administration and management from Harvard University. Previously, Chang was the vice president of corporate affairs at Millendo Therapeutics, a biotech focused on endocrine diseases and the founding managing director for Fast Forward Medical Innovation at Michigan Medicine.